statistiche ricercatore

Continente	#
NA - Nord America	914
AS - Asia	368
EU - Europa	288
SA - Sud America	54
Continente sconosciuto - Info sul continente non disponibili	28
AF - Africa	12
OC - Oceania	5
Totale	1.669

Nazione	#
US - Stati Uniti d'America	901
SG - Singapore	131
IT - Italia	75
CN - Cina	71
BR - Brasile	44
RU - Federazione Russa	38
DE - Germania	37
HK - Hong Kong	35
VN - Vietnam	34
BD - Bangladesh	27
IE - Irlanda	26
GB - Regno Unito	23
FI - Finlandia	20
JP - Giappone	19
SE - Svezia	17
IN - India	14
IR - Iran	11
UA - Ucraina	11
FR - Francia	10
CA - Canada	8
CZ - Repubblica Ceca	6
ID - Indonesia	6
MA - Marocco	5
PL - Polonia	5
BE - Belgio	4
ES - Italia	4
JM - Giamaica	4
KR - Corea	4
NL - Olanda	4
AR - Argentina	3
AT - Austria	3
MY - Malesia	3
NZ - Nuova Zelanda	3
AU - Australia	2
DZ - Algeria	2
EC - Ecuador	2
IQ - Iraq	2
PH - Filippine	2
TR - Turchia	2
TW - Taiwan	2
VE - Venezuela	2
ZW - Zimbabwe	2
AE - Emirati Arabi Uniti	1
BN - Brunei Darussalam	1
CI - Costa d'Avorio	1
CL - Cile	1
CO - Colombia	1
ET - Etiopia	1
GR - Grecia	1
LT - Lituania	1
MD - Moldavia	1
MN - Mongolia	1
MX - Messico	1
OM - Oman	1
PK - Pakistan	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
UY - Uruguay	1
ZA - Sudafrica	1
Totale	1.641

Nome	#
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029	478
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)	231
Computational studies of mutations associated to resistance in HIV-1 macromolecular targets and implications in rational design of novel antiviral agents	229
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses	218
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control	136
Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients	110
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile	101
Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach	85
Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles	81
Totale	1.669

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	59	0	3	0	6	2	5	14	6	5	4	4	10
2022/2023	128	29	11	4	14	8	19	8	14	13	1	4	3
2023/2024	59	5	1	2	1	2	7	5	13	12	2	3	6
2024/2025	274	16	42	32	19	6	24	25	25	38	14	17	16
2025/2026	528	27	30	51	34	49	31	67	81	54	40	23	41
2026/2027	62	54	8	0	0	0	0	0	0	0	0	0	0
Totale													1.669